Evercore Has Lowered Expectations for Insulet (NASDAQ:PODD) Stock Price

Insulet (NASDAQ:PODD) had its price objective cut by analysts at Evercore from $240.00 to $200.00 in a report issued on Thursday, Marketbeat Ratings reports. Evercore’s target price would suggest a potential upside of 29.74% from the stock’s current price.

Other analysts have also recently issued research reports about the company. Raymond James Financial decreased their target price on Insulet from $385.00 to $355.00 and set an “outperform” rating on the stock in a report on Thursday, February 19th. Sanford C. Bernstein decreased their price target on Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a report on Thursday. Leerink Partners decreased their price target on Insulet from $360.00 to $247.00 in a report on Thursday. Canaccord Genuity Group decreased their price target on Insulet from $435.00 to $249.00 and set a “buy” rating on the stock in a report on Thursday. Finally, Robert W. Baird decreased their price target on Insulet from $360.00 to $248.00 in a report on Thursday. Eighteen investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $257.09.

Insulet Price Performance

Shares of PODD stock opened at $154.16 on Thursday. The stock’s fifty day moving average is $211.22 and its 200-day moving average is $263.85. The company has a debt-to-equity ratio of 0.71, a quick ratio of 2.15 and a current ratio of 2.49. The stock has a market capitalization of $10.68 billion, a PE ratio of 35.85, a PEG ratio of 0.92 and a beta of 1.20. Insulet has a 52 week low of $148.30 and a 52 week high of $354.88.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping the consensus estimate of $1.19 by $0.23. The company had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The business’s revenue for the quarter was up 33.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities research analysts expect that Insulet will post 6.46 EPS for the current fiscal year.

Insider Transactions at Insulet

In other news, Director Michael R. Minogue purchased 2,030 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were acquired at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the acquisition, the director directly owned 17,483 shares in the company, valued at approximately $4,304,839.09. The trade was a 13.14% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.36% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Insulet

Several hedge funds have recently added to or reduced their stakes in the company. Winnow Wealth LLC bought a new position in Insulet during the third quarter worth about $862,000. Nordea Investment Management AB boosted its holdings in Insulet by 35.0% during the fourth quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock worth $157,128,000 after buying an additional 142,922 shares during the last quarter. Machina Capital S.A.S. acquired a new stake in shares of Insulet during the third quarter worth about $2,778,000. Jain Global LLC raised its position in shares of Insulet by 148.2% during the third quarter. Jain Global LLC now owns 106,710 shares of the medical instruments supplier’s stock worth $32,945,000 after purchasing an additional 63,719 shares during the period. Finally, ING Groep NV raised its position in shares of Insulet by 88.5% during the third quarter. ING Groep NV now owns 17,300 shares of the medical instruments supplier’s stock worth $5,341,000 after purchasing an additional 8,123 shares during the period.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s Q1 results beat expectations, with revenue of $761.7 million and EPS of $1.42, and management raised full-year revenue growth guidance to 21%–23%, reinforcing momentum in its Omnipod diabetes platform.
• Positive Sentiment: The company highlighted strong international Omnipod growth and continued expansion of Omnipod 5 into new markets, which suggests the core business remains healthy. Article Title
• Neutral Sentiment: Recent earnings-call coverage and transcript coverage continued to emphasize improved profitability and upbeat management commentary following the Q1 report. Article Title
• Negative Sentiment: Multiple Wall Street firms cut price targets sharply after the earnings report, including Piper Sandler, JPMorgan, Citigroup, Wells Fargo, Stifel, Raymond James, Canaccord Genuity, Leerink, and others, which likely pressured the shares.
• Negative Sentiment: The stock is also trading well below several recent analyst targets, and the cluster of downgrades/target reductions may be signaling concerns about valuation or the pace of future upside despite the earnings beat.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.